⌘K
OverviewStock screenerAnalyst actionsCalendar
MarketsInvestorsSign in
StockAustraliaNasdaqGS

TLX

Telix Pharmaceuticals Limited

Healthcare · Biotechnology

12.34USD

+0.3600 (+3.01%)

DescriptionHistoricalFinancialsRelative ValueResearchNewsDiscussionOptionsPrice Chart ↗Fundamental Chart ↗
ProfileRatiosRevenue & EPS
Reading financial statements from SEC filings…
A first visit to a security takes a few seconds.
Fiscal Year End12/2025
Last Quarter End12/2025 Q4
Current/T12M(USD)
1)

Issue Data

Last PxUSD / 12.34
P/E119.8
Dvd Ind Yld—
P/B9.80
P/S5.1
Curr EV/T12M EBITDA63.0
Mkt Cap (USD)4.1B
Curr EV (USD)4.4B
2)

Per Share Data

EPS T12M-0.02
DPS—
Bk Val Per Sh1.44
Rev/Sh2.48
Cash/Sh0.74
Curr Shares Out339.8M
FCF/Sh-0.19
3)

Cash Flow Analysis

P/CF-339.0
Curr P/FCF-66.7
CF/NI1.7
Dvd P/O0.0%
Cash Gen/Cash Reqd—
Csh Dvd Cov—
CFO/Sales-1.5%
Eff Interest Rate19.8%
4)

Growth Potential

Dil EPS 1Y Gr-121.6%
Cap 1Y Gr16.1%
BPS 1Y Gr25.5%
R&D To Sales21.3%
Retention Rate100.0%
Rev 1Y Gr55.6%
FCF 1Y Gr-1250.9%
Assets 1Y Gr23.8%
5)

Profitability

EBITDA0.1B
EBIT0.0B
Operating Margin2.2%
Pretax Margin-0.7%
Net Margin-0.9%
ROA-0.7%
ROE-3.0%
ROC—
Asset Turnover0.76
6)

Structure

Current Ratio1.43
Quick Ratio1.74
Debt/Assets34.8%
Debt/Com Eq97.5%
Net Debt/EBITDA3.77
Tot Debt/Capital49.4%
Gross Margin53.1%
EBIT/Int Exp0.4

Returns and turnover use the AVERAGE balance over the year, not the closing snapshot. Growth rates compare the two most recent fiscal years.